Recently Added |View All
News
Can NST-628 Fill the Treatment Void For Advanced Tumors with RAS or RAF Mutations?
A phase 1 clinical trial underway at Roswell Park Comprehensive Cancer Center will evaluate the potential of a “molecular glue” to treat MAPK pathway-mutated advanced solid tumors in patients who have exhausted standard treatment options.
Video
Advances in Ovarian Cancer Treatment Show Promise for Longer Response, Survival Rates
While it remains the leading cause of death among patients with gynecologic cancers, new treatments are offering patients better outcomes and better quality of life.
News
Clinical Trial Utilizes Novel CAR Target for Relapsed/Refractory Multiple Myeloma
Most multiple myeloma patients with relapsed/refractory disease will undergo CAR T-cell therapy targeting B-cell maturation antigen (BCMA), a protein found on multiple myeloma cells.
News
Encouraging results from a phase 1 clinical trial conducted at Roswell Park Comprehensive Cancer Center between 2019-2020 have laid the foundation for a phase 1/2a study for patients with metastatic or unresectable triple negative breast cancer (mTNBC)
Video
New Clinical Trials for Cervical Cancer Now Available at Roswell Park
Groundbreaking new treatments, including a handful of clinical trials, are now available for patients at Roswell Park Comprehensive Cancer Center, says gynecologic oncologist Karen McLean, MD, PhD, FCAOG.
Video
Immunotherapies, Antibody Drug Conjugants Among Advances in Endometrial Cancer Treatment Options
While the majority of endometrial cancer cases are diagnosed early and patients have an excellent prognosis, those diagnosed with advanced or recurrent endometrial cancer often face a worse prognosis and their treatment can be more difficult.
News
Exclusive to Roswell Park, ‘Armored CAR’ Clinical Trial Targets CD19+ Hematologic Malignancies
A phase 1 clinical trial underway exclusively at Roswell Park Comprehensive Cancer Center will evaluate a novel chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory hematologic malignancies whose tumor ...
Video
Roswell Park Provides Support, Clinical Trials for Young Adult Sarcoma Patients
As a member of the Sunshine Consortium, Roswell Park Comprehensive Cancer Center has access to, and is developing, clinical trials for young adult patients and their particular needs.
News
FDA Expands Orphan Drug Designation for SurVaxM, Immunotherapy Developed at Roswell Park.
The U.S. Food and Drug Administration (FDA) has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center.
This site is intended for healthcare professionals
Download our free mobile app — exclusively for physicians and physician offices — for direct access to a complete, up-to-date directory of Roswell Park physicians wherever you go. Email or call to refer a patient or ask a question with a click of a button.
BROADCASTMED